Check if the authors are on RG:

J Clin Psychiatry. 1994 Dec;55(12):517-22.

Fluoxetine in posttraumatic stress disorder.

van der Kolk BA1, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G.

Author information

Abstract

BACKGROUND:

This study was designed to establish the efficacy of the serotonin reuptake blocker fluoxetine in the treatment of posttraumatic stress disorder (PTSD).

METHOD:

64 subjects (22 women and 42 men; 31 veterans and 33 nonveterans) with PTSD entered a 5-week randomized double-blind trial comparing fluoxetine (N = 33) and placebo (N = 31).

RESULTS:

By Week 5 fluoxetine, but not placebo, significantly reduced overall PTSD symptomatology, as assessed by the Clinician-Administered PTSD Scale (CAPS) score. Changes were most marked in the arousal and numbing symptom subcategories. Non-VA patients responded much better than VA patients. Fluoxetine was an effective antidepressant independent of its effects on PTSD.

CONCLUSION:

Fluoxetine is an effective pharmacotherapeutic agent for treating PTSD and its associated features, particularly in patients without chronic treatment histories.

Fluoxetine in post-traumatic stress disorder: Randomised, double-blind study

• Kathryn M. Connor (a1), Suzanne M. Sutherland (a1), Larry A. Tupler (a1), Mary L. Malik (a1) ...
  • https://doi.org/10.1192/bjp.175.1.17
  • Published online: 03 January 2018

Abstract Background

Most pharmacotherapy trials in post-traumatic stress disorder (PTSD) have been conducted upon male combat veterans. Outcome studies relating to civilians are therefore needed.

Aims

To demonstrate that fluoxetine is more effective than placebo in treating PTSD.

Method

Civilians with PTSD (n=53) were treated for 12 weeks with fluoxetine (up to 60 mg/day) or placebo. Assessments of PTSD severity, disability, stress vulnerability, and high end-state function were obtained.

Results

Fluoxetine was more effective than placebo on most measures at week 12, including global improvement (much or very much improved: fluoxetine 85%, placebo 62%, difference 0.24, 95% CI 0.01–0.47; very much improved: fluoxetine 59%, placebo 19%, difference 0.40, 95% CI 0.16–0.64), and high end-state function (fluoxetine 41%, placebo 4%, difference 0.37, 95% CI 0.17–0.57)

Conclusions

Fluoxetine was superior for measures of PTSD severity, disability, stress vulnerability, and high end-state function. The placebo-group response was low when viewed as a broad outcome based on a portfolio of ratings, but was higher with a traditional global rating criterion.

I sent an email to the author to get the full text, but I have never received a reply. This article is very important to me. I am helpless, I ask for help.

There are several papers that emphasize the importance of fluoxetine (prozac) in post-traumatic stress. I gave you another paper also in my answer. Article Pharmacotherapy for Post-traumatic Stress Disorder In Combat...

Although fluoxetine is recommended as a first-line (off-label) therapy in PTSD,1,19 efficacy results from clinical trials have been variable. For example, Connor et al. reported a superior response with fluoxetine in civilian patients with PTSD,29 and Meltzer-Brody et al. observed that fluoxetine reduced all symptom clusters of the disorder in civilians.30 Martenyi et al., however, found that fluoxetine did not differ significantly from placebo in civilian patients with PTSD.31

Similarly, Hertzberg et al. reported that fluoxetine lacked efficacy, compared with placebo, in combat veterans with PTSD,9 whereas Martenyi et al. noted that fluoxetine was significantly superior to placebo in veterans.32,33

There are also other forms of pharmacotherapy that is supposed to be effective

Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress. 1996;9:865–871

It’s kind of you! Thanks ! Although it is useful to reply to my paper, I still need to get the full text (van der Kolk B A,Dreyfuss D,Michaels M et al. Fluoxetine in posttraumatic stress disorder.[J] .J Clin Psychiatry, 1994, 55: 517-22). In order to extract the data and complete my research and paper.

Van der Kolk is though an old paper (1994), why not change to a newer paper? The van der Kolk abstract is on PubMed but obviously they did not put in full text that early.

Br J Psychiatry. 2015 Feb;206(2):93-100. doi: 10.1192/bjp.bp.114.148551.

Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis.

Hoskins M1, Pearce J1, Bethell A1, Dankova L1, Barbui C1, Tol WA1, van Ommeren M1, de Jong J1, Seedat S1, Chen H1, Bisson JI1.

Author information

Abstract

BACKGROUND:

Pharmacological treatment is widely used for post-traumatic stress disorder (PTSD) despite questions over its efficacy.

AIMS:

To determine the efficacy of all types of pharmacotherapy, as monotherapy, in reducing symptoms of PTSD, and to assess acceptability.

METHOD:

A systematic review and meta-analysis of randomised controlled trials was undertaken; 51 studies were included.

RESULTS:

Selective serotonin reuptake inhibitors were found to be statistically superior to placebo in reduction of PTSD symptoms but the effect size was small (standardised mean difference -0.23, 95% CI -0.33 to -0.12). For individual pharmacological agents compared with placebo in two or more trials, we found small statistically significant evidence of efficacy for fluoxetine, paroxetine and venlafaxine.

CONCLUSIONS:

Some drugs have a small positive impact on PTSD symptoms and are acceptable. Fluoxetine, paroxetine and venlafaxine may be considered as potential treatments for the disorder. For most drugs there is inadequate evidence regarding efficacy for PTSD, pointing to the need for more research in this area.

Royal College of Psychiatrists.

If you are pleased with rat model, then you have a paper from 2017 here. The full text is free in PubMed:

Transl Psychiatry. 2017 Nov 30;7(11):1260. doi: 10.1038/s41398-017-0014-5.

Fluoxetine treatment is effective in a rat model of childhood-induced post-traumatic stress disorder.

Ariel L1,2, Inbar S1,2, Edut S2,3, Richter-Levin G4,5,6.

Author information

Abstract

Although selective serotonin reuptake inhibitors (SSRIs) are first-line treatment for post-traumatic stress disorder (PTSD) patients, their therapeutic efficacy is limited. Childhood adversities are considered a risk factor for developing PTSD in adulthood but may trigger PTSD without additional trauma in some individuals. Nevertheless, just as childhood is considered a vulnerable period it may also be an effective period for preventive treatment. Using a rat model of childhood-induced PTSD, pre-pubertal stress (juvenile stress, JVS), we compared the therapeutic effects of fluoxetine and examined the effectiveness of 1 month of fluoxetine treatment following JVS and into adulthood compared to treatment in adulthood. Since not all individuals develop PTSD following a trauma, comparing only group means is not the adequate type of analysis. We employed a behavioral profiling approach, which analyzes individual differences compared to the normal behavior of a control group. Animals exposed to JVS exhibited a higher proportion of affected animals as measured using the elevated plus maze 8 weeks after JVS. Fluoxetine treatment following the JVS significantly decreased the proportion of affected animals as measured in adulthood. Fluoxetine treatment in adulthood was not effective. The results support the notion that childhood is not only a vulnerable period but also an effective period for preventive treatment.

PMID: 29187754 PMCID: PMC5802710 DOI: 10.1038/s41398-017-0014-5 [Indexed for MEDLINE] Free PMC Article

I am working on a meta-analysis of fluoxetine, I need to include this study, so I really need this paper form and data.

Sorry, I understand now why you need the whole old paper. Perhaps from Cochran library then.

Thank you for understanding! Although I have not obtained the full text now.

Perhaps you can call or fax his assistant:

Angela Lin, Assistant to Bessel van der Kolk PO Box 180501 Boston, MA 02118 617-784-2644 866-308-5904 (fax) [email protected]